LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

April 13, 2018: By Jon Swedien

LENSAR logoLENSAR’s Laser System with Streamline IV has received US FDA 510(k) clearance to perform corneal pockets and flaps for corneal inlay procedures, the Orlando, Florida, company announced April 11.

The system’s new features include a curved-contact patient-interface device that allows surgeons to create the corneal pockets and flaps, LENSAR said.

The company said the device’s new capabilities will be rolled out to US users in 2018.

LENSAR has applied for regulatory approval in the EU and anticipates the new features will be available there in 2018, as well, pending approval, the company said.

The system also features LENSAR’s proprietary augmented reality 3-D model and allows for individual treatment plans, including precise laser delivery and efficient lens fragmentation that can reduce or eliminate the ultrasonic energy delivered into the eye, the company said.

It is the system’s fourth upgrade in two years, LENSAR said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023